Evidence map›Paper›PMID 40986089›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Hannah Warren, Thomas Wagner, Soha El-Sheikh, Nick Campain, Tze M Wah, Tim S O'Brien, Iosif A Mendichovszky, Sabina Dizdarevic, Charlie Stewart, Helen Ng and 25 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Hannah WarrenDivision of Surgery and Interventional Science, University College London, London, UK. h.warren@ucl.ac.uk.ORCID 0000-0002-4106-2705
Thomas WagnerDepartment of Nuclear Medicine, Royal Free Hospital, London, UK.
Soha El-SheikhSpecialist Centre for Kidney Cancer, Department of Histopathology, Royal Free Hospital, London, UK.
Nick CampainDepartment of Urology, Royal Devon University Hospitals NHS Foundation Trust, Exeter, UK.
Tze M WahDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Tim S O'BrienDepartment of Urology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Iosif A MendichovszkyDepartment of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sabina DizdarevicDepartment of Nuclear Medicine, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Charlie StewartDepartment of Urology, Royal Devon University Hospitals NHS Foundation Trust, Exeter, UK.
Helen NgDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
James BlackmurDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Patrick RogersDepartment of Radiology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Andrew ScarsbrookDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Dhruba DasguptaDepartment of Nuclear Medicine, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Fahim Ul-HassanDepartment of Nuclear Medicine, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Nitasha SinghDepartment of Nuclear Medicine, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Ammar AlanbukiDepartment of Urology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Maryam JessopDepartment of Nuclear Medicine, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Linda ParkDepartment of Urology, Royal Devon University Hospitals NHS Foundation Trust, Exeter, UK.
Kelly LeonardDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Alex WoodDepartment of Radiology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Ben ChallacombeDepartment of Urology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Ravi BarodDivision of Surgery and Interventional Science, University College London, London, UK.
Prasad PatkiSpecialist Centre for Kidney Cancer, Urology Department, Royal Free Hospital, London, UK.
Faiz MumtazDivision of Surgery and Interventional Science, University College London, London, UK.
Axel BexDivision of Surgery and Interventional Science, University College London, London, UK.
Veeru KasivisvanathanDivision of Surgery and Interventional Science, University College London, London, UK.
William WildgoosePatient and Public representative, University College London, London, UK.
Sigrun ClarkRapid Research, Evaluation and Appraisal Lab (RREAL), Department of Targeted Intervention, University College London, London, UK.
Cecilia Vindrola-PadrosRapid Research, Evaluation and Appraisal Lab (RREAL), Department of Targeted Intervention, University College London, London, UK.
Elena PizzoDepartment of Applied Health Research, University College London, London, UK.
Hakim-Moulay DehbiComprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK.
Mark EmbertonDivision of Surgery and Interventional Science, University College London, London, UK.
Maxine Gb TranDivision of Surgery and Interventional Science, University College London, London, UK.

Funding

Research for Patient Benefit Programme NIHR203545
6 · The paper itself

Abstract

purpose[

methodsConsecutive adult patients with a newly-diagnosed clinical T1 (cT1) renal mass (2-7 cm) presenting to participating sites December 2022 - February 2024 were recruited and underwent MIBI SPECT/CT prior to histopathological diagnosis. Patients who accepted and declined participation and clinicians involved in study activities were invited to a semi-structured interview. The primary endpoint was feasibility of multi-centre recruitment. Secondary endpoints included qualitative assessment of barriers and facilitators to participation, estimates of MIBI SPECT/CT accuracy to detect cancer in order to power a definitive study, inter-rater agreement and identifying training needs for scan acquisition and interpretation.

resultsOf 109 approached patients, 50 enrolled and underwent the study scan (45.8%, 95% CI 36.2-55.7%) across 6 sites. MIBI SPECT/CT scans were acquired and reported without the need for significant additional training. All scans were of adequate quality for interpretation. Sensitivity and specificity of MIBI SPECT/CT to detect cancer were 97.0% (95% CI 84.2-99.9%) and 53.8% (25.1-80.8%), respectively.

conclusionMULTI-MIBI has demonstrated feasibility of recruitment to a diagnostic evaluation study for T1 renal masses. Preliminary estimates of diagnostic accuracy suggest that MIBI SPECT/CT could reduce the number of patients with benign tumours undergoing surgery without missing a significant number of patients with malignant disease, however these results are limited by the small sample size in this feasibility study and a larger definitive study is needed prior to adoption in practice.

Indexed as

Kidney NeoplasmsSingle Photon Emission Computed Tomography Computed TomographyTechnetium Tc 99m SestamibiAdultAgedAged, 80 and overFeasibility StudiesFemaleHumansMaleMiddle AgedTechnetium Tc 99m SestamibiDiagnostic accuracyOncocytomaRenal cancerSestamibiSPECT/CT

Identifiers

PMID40986089
PMCPMC12860857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.